EpiSwitch PSE Blood Test Reduces Unnecessary Prostate Biopsies: A Real-World Clinical Utility Study
Cancers · 29.06.2025 · 17 (13) · 2193
DOI: 10.3390/cancers17132193 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 29.06.2025. Verfasst von Joos Berghausen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Physiology, Georgetown University Medical Center, 3900 Reservoir Rd NW, Washington, DC 20057, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, Oxford BioDynamics.
Abstract (Originalsprache)
Background/Objectives: Prostate cancer (PCa) remains a major contributor to cancer-related morbidity and mortality worldwide. Current diagnostic strategies, largely based on PSA screening, lack specificity and sensitivity, leading to unnecessary invasive procedures and elevated healthcare costs. This real-world study evaluated the EpiSwitch® PSE assay, a blood-based test analyzing 3D genome conformation signatures, ability to avoid unnecessary biopsies and the resulting clinical and economical benefits.
Methods
187 patients undergoing evaluation for PCa were tested with the EpiSwitch® PSE assay. Biopsy confirmation was available for 53 patients, while predictive modeling assessed 134 patients using EpiSwitch PSE results and clinical variables.
Results
Among the 187 patients evaluated, predictive modeling showed that up to 79.1% (106/134) of patients could safely defer biopsy based on a low-likelihood EpiSwitch PSE result, while an alternative model showed a 66.4% (89/134) biopsy avoidance rate. The PSE result demonstrated strong concordance with biopsy-confirmed diagnoses and was the most influential predictor in multivariate analysis, followed by PI-RADS score. The test achieved a 100% technical success rate, with an average turnaround time of 4.4 days.
Conclusions
Incorporating the EpiSwitch PSE assay into clinical workflows enhances decision-making efficiency, reduces unnecessary biopsies, and improves healthcare resource utilization. These findings support the assay’s strong clinical utility and economic value, highlighting its potential for broader adoption as a minimally invasive reflex test and a pre-biopsy triage tool for the early and accurate detection of prostate cancer. Future studies should include prospective, multicenter trials to confirm these results across broader populations and evaluate longitudinal outcomes of patients managed with PSE-guided care.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology and Physiology, Georgetown University Medical Center, 3900 Reservoir Rd NW, Washington, DC 20057, USA.
- Oxford BioDynamics Inc., 7495 New Horizon Way, STE 110, Frederick, MD 21703, USA.
- Oxford BioDynamics PLC, 3140 Rowan Palace, John Smith Drive, Oxford OX4 2WB, UK.
- Kearney Urology Center PC, 123 West 31st St., Kearney, NE 68847, USA.
Förderung
- NIGMS NIH HHS
- Oxford BioDynamics
Zitieren
APA
Berghausen, J., Abdo, J., Mathis, R., Hunter, E., Akoulitchev, A., & Pohlman, G. D. (2025). EpiSwitch PSE Blood Test Reduces Unnecessary Prostate Biopsies: A Real-World Clinical Utility Study. Cancers, 17(13), 2193. https://doi.org/10.3390/cancers17132193
Vancouver
Berghausen J, Abdo J, Mathis R, Hunter E, Akoulitchev A, Pohlman GD. EpiSwitch PSE Blood Test Reduces Unnecessary Prostate Biopsies: A Real-World Clinical Utility Study. Cancers. 2025;17(13):2193. doi:10.3390/cancers17132193
BibTeX
@article{Berghausen2025,
author = {Berghausen, Joos and Abdo, Joe and Mathis, Ryan and Hunter, Ewan and Akoulitchev, Alexandre and Pohlman, Garrett D},
title = {EpiSwitch PSE Blood Test Reduces Unnecessary Prostate Biopsies: A Real-World Clinical Utility Study},
journal = {Cancers},
year = {2025},
volume = {17},
number = {13},
pages = {2193},
doi = {10.3390/cancers17132193}
}
EUVIMED